DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial - Test2 - elhamkhani - TriplyDB

DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial

DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial

http://www.wikidata.org/entity/Q34663554

about

Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles Effect of vaccine administration modality on immunogenicity and efficacy.Efficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules.Molecular mechanisms for enhanced DNA vaccine immunogenicity.Phase 1 study of pandemic H1 DNA vaccine in healthy adults The influence of delivery vectors on HIV vaccine efficacy Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccination CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model Toll-Like Receptor 9 Activation Rescues Impaired Antibody Response in Needle-free Intradermal DNA Vaccination Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector.Needle-free delivery of macromolecules through the skin using controllable jet injectors.Recent Developments in Preclinical DNA Vaccination.DNA Immunization for HIV Vaccine Development.MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice.Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.Characterization of T-cell responses to cryptic epitopes in recipients of a noncodon-optimized HIV-1 vaccine An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.A Review of DNA Vaccines Against Influenza DNA vaccines against tuberculosis One Group's Historical Reflections on DNA Vaccine Development

P2860

Q27311290-85E197E6-977D-42D8-8651-6FFC526A2821 Q27692376-9A07A670-5DC1-4286-8239-22E3836FDDCF Q30204348-6B31DE95-AF03-4C99-9129-647D0CA9BEB9 Q30366743-580A4EB9-7EF7-4EFF-AE21-DF57DF90990F Q30373824-EDD1652B-C58C-4F15-A187-AA3F6D536F45 Q34077543-59F05FA0-52B8-401C-949F-9C7BDBD4B9F1 Q34263835-F9DACAE5-EC84-479D-AB6E-28B4C29E66FA Q35118834-F8E56715-5577-4BE3-81EB-CDB7D7E428F8 Q35762443-5A9502D5-7C8C-46E2-8F45-CF3418148622 Q36369631-2C498A8A-B835-4488-A48F-EDC7BD2FD1F7 Q36901422-19A741E7-D5AD-4E75-960E-231A964DD24B Q37277900-ECB322A8-8760-4CEC-A589-9ACA1BB6C4EB Q37381632-6C907C1A-7CBE-4AEE-9D9C-7DFC70462A2F Q38500859-3A85A17A-3AA5-4CCB-B9AB-3E7CA87143AE Q38581976-E06DB2D0-86F9-480D-BF41-79FDDE279CD7 Q38581981-E8245FF1-1EAE-4508-94FD-BB6E8E736566 Q38892738-F89B6775-A544-4BED-878A-B8A824C79292 Q40068135-792F29E6-F518-48D7-84C9-8E5F81B4BD9F Q41881198-EF429955-C26C-4420-A8A9-FABCB14D524B Q47105782-34BC84FD-FF50-4C0B-AD66-2428AF2B834D Q55154648-A9F5C484-8E90-4F8F-B992-7E5A364E66C1 Q57094261-A95D9D45-A7DC-42D9-83AA-5C4DD4919C0F Q57203104-14A335D8-28D3-4495-9539-9EF94CAB1B66 Q58731456-F91D6A75-5F00-478C-911F-D90932781240

P2860

DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial

http://www.wikidata.org/entity/Q34663554

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

DNA vaccine delivered by a nee ...... in a randomized clinical trial

@ast

DNA vaccine delivered by a nee ...... in a randomized clinical trial

@en

DNA vaccine delivered by a nee ...... in a randomized clinical trial

@nl

type

label

DNA vaccine delivered by a nee ...... in a randomized clinical trial

@ast

DNA vaccine delivered by a nee ...... in a randomized clinical trial

@en

DNA vaccine delivered by a nee ...... in a randomized clinical trial

@nl

prefLabel

DNA vaccine delivered by a nee ...... in a randomized clinical trial

@ast

DNA vaccine delivered by a nee ...... in a randomized clinical trial

@en

DNA vaccine delivered by a nee ...... in a randomized clinical trial

@nl

P1433

Q34663554-DA9D8190-C190-4262-97B4-AF8FC482B928

P1476

Q34663554-B8BA4220-D0BB-4472-A282-29FC6E7E7AB0

P2093

Q34663554-40F73F89-950D-46AA-BE72-991C70BA0202

Q34663554-4F338864-764B-4657-A340-B2A97DBFD794

Q34663554-7E132C83-1B9A-4FEE-90E8-6D6858F6D096

Q34663554-A0EADE29-3864-4533-90AF-E9C6B30B81F2

Q34663554-C60FBEE2-FD1A-4771-BE77-0C329CE266B8

Q34663554-D02268A3-64ED-4DCD-835D-F39C404B8A93

Q34663554-D0319F16-07A0-4308-8B63-0CB9BBF3B24C

Q34663554-E2E20DFC-C5A5-45EA-B19C-8A800364B26D

Q34663554-EB01E27E-0C8A-496A-891E-2B3E04327EE6

P2860

Q34663554-037F5DBB-24AD-4C6D-8EB9-5541E1931726

Q34663554-0B839A35-47D7-4ACD-ADA2-E7CC71248577

Q34663554-0F25FEE3-ED6A-4CC2-A540-485489B0C0F7

Q34663554-1A6C8808-16F1-4A5C-A8AC-DEAF6D78C2BF

Q34663554-1BE8F57B-692E-4AEA-BB81-6C314D3C27D5

Q34663554-1E9F671C-8E43-48FE-AC43-60ABB86743DE

Q34663554-5B38FBE1-81A9-494C-BF80-48F86DEEF9F2

Q34663554-5EB7F0BF-74F2-42FF-89A0-1A66B3E65ECC

Q34663554-610DDB59-78D6-4D41-8ACC-A4445A06AB09

Q34663554-644B4D4D-1372-4B1B-974B-95549F24FF2E

P304

Q34663554-BEA26756-41A6-41AE-AAC5-14ACFA3EAEE9

P31

Q34663554-5A688736-4E42-4640-8ECF-549E3DCC3BE4

P356

Q34663554-2DA7C3A5-4348-486B-AB33-75686A2A3601

P407

Q34663554-32975F13-EAF2-4599-8D38-9F6BA709D18A

P433

Q34663554-09095FB4-89BC-463B-9A9C-75B96FCD7D5D

P478

Q34663554-A9AA42F6-F22C-4626-93B6-A26CF4648B1D

P50

Q34663554-425D9C3E-3BFC-4D34-AA7F-B8ACEED83AAD

Q34663554-52097E08-CE10-41D9-AD27-E4716ABD43F8

Q34663554-56D0B640-D371-45E3-8FF5-F2ECFF84394B

Q34663554-75D9763B-2A20-49A6-80F3-237648CF190D

P577

Q34663554-0EAB78EF-DBDA-481C-AB6D-962FCE2C9AE8

P5875

Q34663554-EB6A9703-2487-4F18-BC6B-5BF72257DB61

P698

Q34663554-075F8564-5748-4994-BA9D-15955408CE32

P921

Q34663554-AB9DFC3B-AC15-4EB3-A679-5DCBA4F15FCE

P932

Q34663554-7AC49916-51E2-4E47-8316-E35C7FE9DB23

P356

JOURNAL.PONE.0059340

P1433

P1476

DNA vaccine delivered by a nee ...... in a randomized clinical trial

@en

P2093

Ingelise J Gordon

http://www.w3.org/2001/XMLSchema#string

Mario Roederer

http://www.w3.org/2001/XMLSchema#string

Martha C Nason

http://www.w3.org/2001/XMLSchema#string

Mary E Enama

http://www.w3.org/2001/XMLSchema#string

Richard A Koup

http://www.w3.org/2001/XMLSchema#string

Robert T Bailer

http://www.w3.org/2001/XMLSchema#string

Sarah A Plummer

http://www.w3.org/2001/XMLSchema#string

Sheila A Peel

http://www.w3.org/2001/XMLSchema#string

VRC 008 Study Team

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)

In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.

Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)

P304

e59340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0059340

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Julie Ledgerwood

Barney S. Graham

P577

2013-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236649851

http://www.w3.org/2001/XMLSchema#string

P698

23577062

http://www.w3.org/2001/XMLSchema#string

P921

P932

3620125

http://www.w3.org/2001/XMLSchema#string